Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026)
Q32 Bio's quarterly Income from Continuing Operations came in at 7722000.0 in Q1 2026, up 30.0% year-on-year from 5940124.27 in Q1 2025, and down 113.38% quarter-over-quarter from 57730000.0 in Q4 2025.
Q32 Bio has reported Income from Continuing Operations for 10 years, with the latest figure at 7722000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 30.0% year-over-year to 7722000.0; the trailing twelve-month figure through Mar 2026 stood at 33130000.0 (up 156.78% YoY), and the FY2025 full-year result was 29821000.0, up 164.68% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 7722000.0, down from 57730000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 92663000.0 in Q1 2022, with the low at 34570000.0 in Q4 2022.
- Average Income from Continuing Operations over 5 years is 4660941.18, with a median of 11031000.0 recorded in 2025.
- Year-over-year, Income from Continuing Operations jumped 8735.88% in 2022 and tumbled 1015.44% in 2025.
- Tracing QTTB's Income from Continuing Operations over 5 years: stood at 34570000.0 in 2022, then rose by 21.52% to 27132000.0 in 2023, then jumped by 47.7% to 14189000.0 in 2024, then jumped by 506.86% to 57730000.0 in 2025, then plunged by 113.38% to 7722000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7722000.0 (Q1 2026), 57730000.0 (Q4 2025), and 7389000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | -7.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.72 Mn |
| Dec 31, 2025 | 57.73 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | -14.19 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -15.53 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.57 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.66 Mn |
| Dec 31, 2021 | -33.58 Mn |
| Sep 30, 2021 | -30.61 Mn |
| Jun 30, 2021 | -30.50 Mn |
| Mar 31, 2021 | -1.07 Mn |
| Dec 31, 2020 | -29.79 Mn |
| Sep 30, 2020 | -28.23 Mn |
| Jun 30, 2020 | -35.34 Mn |
| Mar 31, 2020 | -35.33 Mn |
| Dec 31, 2019 | -24.17 Mn |
| Sep 30, 2019 | -29.63 Mn |
| Jun 30, 2019 | -26.27 Mn |
| Mar 31, 2019 | -23.85 Mn |
| Dec 31, 2018 | -18.79 Mn |
| Sep 30, 2018 | -14.15 Mn |
| Jun 30, 2018 | -12.43 Mn |
| Mar 31, 2018 | -10.22 Mn |
| Dec 31, 2017 | -11.91 Mn |
| Sep 30, 2017 | -6.53 Mn |
| Jun 30, 2017 | -6.00 Mn |
| Mar 31, 2017 | -4.68 Mn |